# A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

Source: https://onco.cc/trials/nct02151084/  
OnCo record `nct02151084` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of gemcitabine, cisplatin and selumetinib in gallbladder cancer and other biliary tract cancers, run by University Health Network, Toronto, active and no longer recruiting.

## Summary

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer is a phase 2, randomised interventional study registered as NCT02151084 by University Health Network, Toronto, with a registry enrolment figure of 57 participants, started 2014-11 and due to reach its primary completion in 2027-05. Interventions recorded: Selumetinib, Cisplatin, Gemcitabine. Conditions listed: Biliary Tract Carcinoma, Gallbladder Carcinoma. Sites: Canada. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT02151084
- Phase: 2
- Setting: A Randomized Phase II Trial of MEK Inhibitor Selumetinib (AZD6244) Combined Continuously or Sequentially With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Patients With Advanced Biliary Cancer
- Sponsor: University Health Network, Toronto
- Enrolled: 57

## Sources

- ClinicalTrials.gov NCT02151084: https://clinicaltrials.gov/study/NCT02151084

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Selumetinib](https://onco.cc/drugs/selumetinib/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct02151084.json